Recent withdrawals of prescription drugs from clinical use because of unexpected side effects on the heart have highlighted the need for more reliable cardiac safety pharmacology assays. Block of the human Ether-a-go go Related Gene (hERG) ion channel in particular is associated with life-threatening arrhythmias, such as Torsade de Pointes (TdP). Here we investigated human cardiomyocytes derived from pluripotent (embryonic) stem cells (hESC) as a renewable, scalable, and reproducible system on which to base cardiac safety pharmacology assays. Analyses of extracellular field potentials in hESCderived cardiomyocytes (hESC-CM) and generation of derivative field potential duration (FPD) values showed dose-dependent responses for 12 cardiac and noncardiac drugs. Serum levels in patients of drugs with known effects on QT interval overlapped with prolonged FPD values derived from hESC-CM, as predicted. We thus propose hESC-CM FPD prolongation as a safety criterion for preclinical evaluation of new drugs in development. This is the first study in which dose responses of such a wide range of compounds on hESC-CM have been generated and shown to be predictive of clinical effects. We propose that assays based on hESC-CM could complement or potentially replace some of the preclinical cardiac toxicity screening tests currently used for lead optimization and further development of new drugs.
Introduction
The pharmaceutical industry currently generates large libraries of "new chemical entities" (NCEs) with the aim of selecting those most promising for clinical trials. Distinguishing specific from detrimental off-target effects at an early stage has the potential to accelerate clinical introduction, improve drug safety, and reduce drug development costs.
The heart has proven to be particularly sensitive to offtarget, life-threatening toxic effects of noncardiac drugs. Over the past several years, reports of unexpected druginduced ventricular arrhythmias associated with sudden cardiac death have led to the withdrawal of a number of drugs from the market, while for many others, additional safety labels have been required to warn of potential risk (Redfern et al., 2003) .
An important determinant for development of Torsade de Pointes (TdP) is prolongation of the QT interval indicating delayed ventricular repolarization. This is defined as the period between the beginning of the QRS complex (depolarization of the ventricles) and the end of the T-wave (repolarization of the ventricles) on an electrocardiogram (ECG). In 1998 the Food and Drug Administration (FDA) defined prolongation of the QT interval on an ECG as a major drug safety issue. Currently, assessing risk for QT interval prolongation is part of the standard preclinical evaluation of NCEs as defined by the International Conference of Harmonization (ICH) Expert Working Group in topic S7B for all drugs in development (Bode and Olejniczak, 2002; Cavero and Crumb, 2005) .
Drug-induced long QT is most commonly induced by affecting the rapid potassium current I kr by binding to the hERG ion channel (Moss and Kass, 2005; Roden et al., 1996) . For both cardiac and noncardiac drugs, primary canine or rabbit Purkinje fibers or cell lines ectopically expressing the hERG ion channel are the preclinical in vitro test systems currently available. Species differences, or the lack of complex ion channel interactions in transgenic cell lines, reduce the predictive value of these systems. For example, determination of the IC 50 value for a drug compound in transgenic cell lines oversimplifies a complex process that is state, time, and voltage dependent. Some drugs like dofetilide require channel activation to reduce the hERG current (Weerapura et al., 2002) , while others, like fluvoxamine, interact exclusively with a closed channel. Finally, not all drugs that block hERG channels in these cell systems carry an arrhythmogenic risk; one well-known example is verapamil (Redfern et al., 2003) . Also of note: many antiarrhythmics can interact with multiple ion channels simultaneously. In addition to potassium channels, the activity of a heart cell is largely dependent on sodium and calcium channels. Whereas activation of sodium channels is required for the generation of an action potential, inward Ca 2+ currents through (L-type) calcium channels counterbalance outward potassium currents in the repolarization phase. To illustrate the complexity of predicting QT prolongation, a recent comparison of 10 drugs on dog Purkinje fibers demonstrated a wide range of effects on QT time, ranging from 158% prolongation to 16% shortening, while all compounds blocked hERG channels by more than 50% (Martin et al., 2004) .
Together, these findings emphasize the importance of assessing preclinical cardiotoxic responses to drugs on cells that closely resemble functional cardiomyocytes of the human heart. Moreover, any alternatives to the current models must be scalable, reproducible, and preferably from an inexhaustible source. Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) have this potential (Denning and Anderson, 2008) . Embryonic stem cells can differentiate to all somatic cell types including cardiomyocytes and in recent years, much effort has been put into developing efficient and reproducible differentiation protocols and methods for cardiomyocyte enrichment from differentiated cell populations (Anderson et al., 2007; Huber et al., 2007; Xu et al., 2008) . Here, we describe the use of hESC-CM in a medium-throughput screening system using microelectrode arrays (MEAs) to determine action potential duration or QT interval by measuring extracellular field potentials. We provide a first validation of the system, using a selection of drugs previously associated with QT prolongation and/or TdP during clinical use in humans. We show that hESC-CM, as used here, can recapitulate drug toxicity mediated through human ion channels and therefore represent an opportunity for preclinical NCE evaluation.
Results

Validation of hESC-CM
Coculture of HES2 and HES3 cells with visceral endoderm-like END-2 cells is among the most efficient ways to produce enriched cultures of hESC-CM (Mummery et al., 2003; . Using an optimized serum-and insulinfree protocol, cultures containing ∼ 25% cardiomyocytes can be reproducibly obtained within 12 days of initiating differentiation (Freund et al., 2007; Mummery et al., 2007; .
To test the cardioactivity of drugs, it is important that the electrical properties of the target cell are known. We therefore first analyzed action potentials of HES3-derived cardiomyocytes using patch clamp electrophysiology, as described previously (Mummery et al., 2003) . Cells were designated as ventricle-like, atrial-like, or pacemaker-like based on the shape of the action potential (AP) defined by the following parameters: amplitude, maximal repolarization, maximum increase in AP (dV/dt max ), AP duration (APD90), and the overall pattern of the AP compared to those recorded in cells from 16 week human fetal hearts (De Sousa Lopes et al, 2006; Mummery et al., 2003) . Ventricularlike APs characteristically show a plateau phase that results in longer repolarization compared to the more triangular shaped, atrial-like APs. Pacemaker-like cells are characterized by slow upstroke velocities and smaller amplitudes. As described previously for the HES2 cell line (Mummery et al., 2003) , cardiomyocytes generated from the HES3-END-2 cocultures were almost exclusively ventricular-like ( Fig. 1a ). An example of a typical action potential is shown in Fig. 1b . We therefore concluded that these relatively homogeneous populations of cardiac ventricular cells may be particularly suitable for drug cardiotoxicity screening.
Traditional patch clamp electrophysiology, the most accurate measure of the properties of electrically excitable cells, requires precise positioning of the electrode on the plasma membrane to enable gigaohm seals to form between the electrode and the cell. However, this is labor intensive, limited to individual cells, and therefore unsuitable for medium/high-throughput drug screens. The more sophisticated planar patch clamp systems are potentially suitable but are difficult to implement since they require purified single cell suspensions. Measurement of external field potentials generated by clumps of beating cardiomyocytes derived from hESC, rather as an electrocardiogram on patients, represents an attractive alternative to conventional patch clamp analyses of APs that is amenable to medium throughput modalities. The signal recorded with one of the extracellular electrodes integrated into the substrate reflects local changes of the membrane potential in a cluster of electrically connected cardiomyocytes (Figs. 1c-f). An example of a field potential is shown in Fig. 1g . Parameters such as the field potential duration (FPD) are easy to define and measure and are directly linked to the action potential duration.
Drug effects on hESC-derived cardiomyocytes
To determine whether hESC-CM would be a useful model for detecting drug-induced QT elongation we first profiled field potential duration in response to selective ion channel blockers. Lidocaine was used to block I Na , nifidipine to block I CaL , and E-4031 for I Kr . As expected, lidocaine did not affect the FPD in three independent experiments; however, it caused cessation of beating in the 30-100 μM concentration range (data not shown). This is in agreement with a published I Na IC 50 for lidocaine of 61 μM (Hill et al., 1989) and with a study of Satin et al., who described initiation of the spontaneous action potentials in hESC-CM by the sodium current (Satin et al., 2004) .
Nifidipine, a typical L-type calcium channel blocker, reproducibly induced a dose-dependent shortening of the FPD, which was initiated at 10 nM and saturated at 1 μM in three independent experiments (Figs. 2c and d). In 3 out of 4 independent experiments loss of spontaneous activity was observed between 300 nM and 1 μM, indicating the importance of a strong inward calcium current for cyclic contraction. Concomitant with decreased FPD, we observed a higher beating frequency but no arrhythmic behavior.
E-4031 is a specific blocker of the hERG channel. In four independent experiments E-4031 induced sustained prolongation of the FPD at concentrations of 30 nM and higher (Figs. 2e and f). At concentrations of 1-3 μM, early after-depolarizations (EADs), which indicate an increased tendency for arrhythmia, were observed in 3 out of 4 experiments (data not shown). Beating frequency was not affected at nanomolar concentrations; however, at higher concentrations it was reduced, indicating a concomitant nonspecific ion-channel block.
Responses to repolarization-prolonging antiarrhythmic drugs
A large class of cardioactive drugs is used clinically to treat arrhythmias. These drugs are classified in four categories and, except for category II (beta-adrenergic receptorblocking), their mechanism of action is related to ionchannel block. We tested two compounds, quinidine (class Ia) and D,L-sotalol (Classes II and III) for their effects on field potential profiles. Quinidine administration to patients is strongly associated with TdP (1-8.8%) (Redfern et al., 2003) . In hESC-CM it induced a dose-dependent FPD prolongation ( Fig. 3a) . At the estimated unbound therapeutic plasma concentration (ETPC unbound) which is 0.9-3.2 μM, we observed a 20-50% increase in QT time which was further prolonged at higher concentrations. D,L-sotalol administration to patients is also strongly associated with TdP (1.8-4.8%); it also induced a dose-dependent FDP prolongation in hESC-CM. At the ETPC unbound (1.8-14 μM) we observed a 15-20% FPD prolongation, which increased at higher concentrations (Fig. 3b ). In summary, both drugs prolonged the FPD at physiologically relevant plasma concentrations, as expected.
Responses to noncardiac drugs associated with TdP or QT prolongation
In addition to repolarization-prolonging antiarrhythmic drugs, where QT prolongation is the desired effect, a large class of (noncardiac) drugs prolongs the QT interval as a detrimental side effect. These drugs derive from various therapeutic areas and include but are not limited to antihistamines, antipsychotics, and antimicrobial agents.
Here we tested cisapride, sparfloxin, terfenadine, domperidone, and sertindole, all of which are associated with QT prolongation and/or TdP as a side effect. Although the clinical incidence of TdP for all of these drugs is low, cisapride and terfenadine have been withdrawn from the Example of field potential raw data; note the reduction of field potential duration at higher concentrations of nifidipine. (e) FPD-dose relationship for hESC-CM in the presence of increasing amounts of E-4031. (f) Example of field potential raw data; note the prolongation of field potential duration in response to E-4031. market because of negative risk/benefit analyses. Cisapride is a serotonin 5-HT4 agonist which increases acetylcholine release in the enteric nervous system and was used for the treatment of a number of gastrointestinal disorders, particularly gastro-esophageal reflux disease in adults and children. In a market span of 12 years, 384 cases of ventricular arrhythmias due to TdP were reported, giving a TdP incidence of 1/120 000 (Darpo, 2001) . The ETPC unbound is 2.6-4.9 nM (Redfern et al., 2003) . At this concentration we observed no effects on the FPD (Fig. 4a ). However, at higher concentrations sustained prolongation of the FDP was observed (Fig. 4a) .
Sparfloxacin is an antibiotic used for the treatment of bacterial infections. The ETPC unbound is 0.19-1.76 μM which overlaps with published IC 50 values (0.23-34.4 μM). This would classify sparfloxacin with repolarization-prolonging antiarrhythmics in a conventional hERG assay. However, in integrated safety analysis of data from 6 multicenter phase III trials, QTc (heart rate corrected QT interval) prolongation (10 ± 24 ms) occurred in 1.1% of the patients. There were no ventricular arrhythmias related to QTc prolongation in any of these patients (Lipsky et al., 1999) . In hESC-CM we found no FDP prolongation at the ETPC unbound but only at higher concentrations (Fig. 4b) , thus supporting the toxicity screening potential of the hESC-CM model as used here. Terfenadine, an antihistamine used for the treatment of allergies, is a "prodrug" and generally metabolized to the active form fexofenadine by intestinal CYP3A4. The association with TdP is low with an occurrence of once in 10 000 person years. Nevertheless the compound has been withdrawn from the market due to perceived risks. The ETPC unbound is 0.1-0.29 nM. However, in cases of genetic deficiencies or induced CYP3A4 inhibition (e.g., grapefruit juice or erythromycin) terfenadine concentrations in human plasma may reach 100 nM (Roy et al., 1996) . At this higher concentration, we observed 10% FPD prolongation (Fig. 4c) . At even higher concentrations, we observed a further increase, followed by a dose-dependent reduction of FPD at micromolar concentrations. The shortening is most likely a result of calcium channel block (Liu et al., 1997) . Domperidone is an antidopaminergic drug administrated orally, rectally, or intravenously to suppress nausea and vomiting. TdP has been reported sporadically and solely with intravenous use (Drolet et al., 2000; Osborne et al., 1985) . The ETPC unbound is 5-19 nM; at this concentration there is only a minor prolongation of the FPD (Fig. 4d) . At higher concentrations, however, there is a biphasic dose-dependent FPD prolongation that suggests block of multiple channels (Fig. 4d ).
Finally we tested the effects of sertindole. Sertindole is a drug used for the treatment of schizophrenia but was withdrawn from the market in 1998 after concern on the high rate of proven or suspected TdP. After reevaluation of existing data and new clinical data, sertindole was reintroduced to the European market in 2002 (Lindstrom et al., 2005) . We did not observe FDP prolongation at the ETPC unbound (0.02-1.59 nM) and even at higher concentrations, only a relatively weak FPD prolongation was observed (Fig.  4e) . In summary, all of these compounds showed effects on the FPD interval, although in general, this was at concentrations higher than the ETPC unbound. This correlates well with the overall very low incidence of TdP induced by these drugs. In general, for these drugs a wide safety margin between plasma concentrations and side effects on cardiomyocytes would be advisable. Induction of TdP due to overdosing or disturbed metabolism (see, for example, terfenadine) is not acceptable and has led to numerous drug failures.
Responses to drugs not associated with TdP in man
Next we investigated two drugs not clinically associated with QT prolongation or TdP (as negative controls). Ketoconazole is a drug used to treat a variety of fungal infections and there is no evidence that it causes TdP or QT prolongation. However, ketoconazaole is a strong inhibitor of cyp34a and may therefore be involved in drug-drug interactions associated with TdP (for example, terfenadine). We observed no FPD prolongation in hESC-CM in the concentration range of 0.3 nM-30 μM, as expected ( Fig.  5a ). Verapamil is a class IV antiarrhythmic used clinically to treat atrial tachyarrhythmias. The compound exerts its action by blocking calcium channels but is also a potent hERG blocker. In fact the narrow safety margin between the ETPC unbound (25-81 nM) and the hERG IC 50 (140-830 nM) would make this compound a false positive in conventional hERG assays (Redfern et al) .
At the ETPC unbound concentration (25-81 nM) we observed a minor FPD shortening which was amplified at higher concentrations (Fig. 5b) . Neither of the negative controls in the assay caused any FPD prolongation.
Discussion
Efficient, reproducible differentiation of hESC to ventricular cardiomyocytes, preferably phenotypically similar to adult human cardiomyocytes, is of critical importance for implementing hESC-CM technologies in drug cardiotoxicity screening. Previously we have shown that the hESC-END-2 coculture system is a very efficient and reproducible method for cardiac lineage differentiation, in particular to ventricularlike cells. Here we show that these cardiomyocyte populations are phenotypically homogeneous, have strong electro-physiological responses, and are suitable for drug safety pharmacology.
Previously, we and others have discussed the immaturity of hESC-CM compared to the human adult heart (Denning and Anderson, 2008; Mummery et al., 2003; Passier et al., 2008; Satin et al., 2004) . In a previous study we disaggregated beating areas that had formed during 12 days of differentiation and found by patch clamp electrophysiology that the cells were comparable to 16-week fetal ventricular cardiomyocytes (Mummery et al., 2003) . One of the major differences between hESC-CM and mature cardiomyocytes is their relatively low resting potential. This means that Na v 1.5 sodium channels can be spontaneously activated resulting in AP generation (Satin et al., 2004) . Finally, the Figure 4 hESC-CM responses to drugs associated with QT prolongation or TdP. FPD-dose relationship for hESC-CM in the presence of increasing amounts of (a) cisapride, (b) sparfloxacin, (c) terfenadine, (d) domperidone, and (e) sertindole. The gray areas are indicative of the ETPC unbound measured in patients and the black line indicates hERG IC 50 . Dotted lines indicate the 95% confidence interval of the fitted curve. ETPC unbound and hERG IC 50 data are adapted from Redfern et al., 2003. initial upstroke velocity of the AP is relatively small due to a lower I Na current compared to adult cardiomyocytes. Importantly, chronotropic responses of dissociated hESC-CM are comparable to human fetal ventricular cells. This was demonstrated by decreased beating frequency following treatment with the cholinergic agonist carbachol, whereas adrenergic agonists phenylephrine and isoprenaline increased beating frequency (Mummery et al., 2003) . Interestingly, despite the relatively immature phenotype of hESC-CM, we found that the drug responses were highly predictive of clinically observed cardiotoxic effects. To validate hESC-CM as a potentially useful new in vitro test system for QT prolongation and TdP, we performed dose escalation studies for a number of drugs known to prolong the QT interval as a therapeutic or side effect. Two previous studies also used hESC-CM in combination with the MEA system to measure drug responses (Caspi et al., 2009; Reppel et al., 2005) but none of them compared a number of compounds systematically over a wide concentration range in dose-dependent manner. As a starting point, we used three drugs that block sodium, calcium, and hERG potassium channels. As expected lidocaine, a classical sodium channel blocker, caused dosedependent cessation of beating at 30-100 μM. Nifidipine, a classical calcium channel blocker, reduced the FPD in a dosedependent fashion and E-4031 increased the FPD by blocking the hERG channel. Interestingly we observed arrhythmic behavior in 3 of 4 independent beating areas in response to high E-4031 concentrations. E-4031 was developed as novel class III antiarrhythmic but this development was stopped for reasons that have remained undisclosed. Most importantly, hESC-CM behavior was reproducible, although a wide variety of field potential shapes was observed. This illustrates that hESC-CM as a model can be used to investigate the effects of drugs on various ion channels present in cardiomyocytes.
Having validated the different ion channel responses, we then profiled a series of drugs that fell into one of three categories: (1) repolarization-prolonging antiarrhythmics, (2) drugs associated with QT prolongation or with TdP as a clinical side effect, and (3) drugs not associated with QT prolongation or TdP (negative controls). Quinidine and D,L-sotalol are both used therapeutically to prolong the QT interval, but are also strongly associated with arrhythmias. Both D,L-sotalol and quinidine induced prolongation at concentrations relatively close to the ETPC unbound. D,L-Sotalol is especially interesting since the hERG IC 50 data (74 uM) are clearly distinct from the ETPC unbound (1.8-14 μM). Therefore, despite the strong association with QT prolongation and TdP, a conventional hERG assay would predict no QT effect of the compound at therapeutic plasma concentrations. Quinidine showed a massive prolongation of the field potential at concentrations higher than the ETPC unbound. Quinidine ion channel interactions are known to be complex. In addition to its blocking effect on hERG, quinidine blocks inward calcium current (I Ca ), the rapid (I Kr ) and slow (I Ks ) components of the delayed potassium rectifier current, the inward potassium rectifier current (I KI ), the ATP-sensitive potassium channel (I KATP ), and I to (Nenov et al., 1998) . Furthermore, quinidine-induced I Na block has been shown to increase at higher beating frequencies, dependent on the ion-channel state (Roden et al., 1987) . It has a low affinity for the resting state, avidly blocks open channels, but does not bind significantly to inactivated sodium channels (Hondeghem and Matsubara, 1988; Tsujimae et al., 2004) . Nevertheless its net effect is prolongation of the AP in normal and diseased hearts, which was clearly shown in the hESC-CM.
Addition of drugs from the second category, domperidone, sparfloxacin, and cisapride to hESC-CM, had a clear effect on the FPD interval. Interestingly in contrast to the repolarization-prolonging drugs tested here the effective concentration triggering FDP prolongation was always higher than the ETPC unbound, which might explain the low incidence of TdP in patients taking these drugs. Although both sertindole and terfenadine, drugs from the same category, had only minor effects on the FPD interval this may nevertheless indicate functional interactions with ion channels. Terfenadine caused a minor prolongation of the FPD interval followed by a shortening at higher concentrations. This is in agreement with guinea pig ventricular myocyte data where terfenadine has also been described as causing a small, but significant, prolongation of APD90 at 100 nM and 1 μM at 1 Hz stimulation frequency, while at higher concentrations, AP duration was shortened (Terrar et al., 2007) . In the same study, dog Purkinje fibers showed no significant effects after terfenadine administration (Terrar et al., 2007) . In conclusion; we observed FPD changes for all tested drugs without exception but always at a higher concentration than the ETPC unbound. This was distinct from the repolarization-prolonging drugs where we observed FPD changes at the ETPC unbound. We therefore hypothesize Figure 5 hESC-CM responses of drugs not associated with TdP. FPD-dose relationship for hESC-CM in the presence of increasing amounts of (a) ketoconazole, and (b) verapamil. The gray areas indicate the ETPC unbound measured in patients and the black line indicates hERG IC 50 . Dotted lines indicate the 95% confidence interval of the fitted curve. ETPC unbound and hERG IC 50 are adapted from Redfern et al., 2003. that drugs with a low proarrhythmic potential (ability to induce TdP) can act synergistically with known proarrhythmic risk factors such as silent mutations, drug-drug interactions, heart failure, ventricular hypertrophy, hypomagnesemia, hypokalemia, hypocalcemia, hypoxia, or acidosis. The combination of any of these factors can induce TdP in patients taking these medicines (Roden et al., 1996; Roden and Viswanathan, 2005) . Finally, addition of the negative control drugs verapamil and ketoconazole to hESC-CM did not result in FPD prolongation, as expected. The fact that verapamil did not prolong the FP interval is of interest since the close margin between the ETPC unbound (25-81 nM) and the hERG IC 50 (140-830 nM) would suggest differently. Therefore verapamil is a classic "false positive" in a conventional hERG assay.
Previously, an association of 1.93 (95% CI: 1.89-1.98) between the anti-hERG activity of drugs, measured as log10 (ETCP unbound/IC 50 ), and the reports of serious ventricular arrhythmias and sudden death to the WHO-UMC database was found (De Bruin et al., 2005) . In another study, a 30-fold safety margin (between the hERG IC 50 and the ETPC unbound) was established as providing an acceptable degree of safety (Redfern et al., 2003) . Using hERG IC 50 as criteria, both verapamil and sparfloxacin would be classified incorrectly. Verapamil was introduced to the market in 1982 and has not been associated with TdP. This is likely the result of multiple channel blocks, which compensate the hERGblocking effect. In fact we observed a shortening of the FPD in hESC-CM, which is in agreement with clinical data (Fauchier et al., 1999) . Sparfloxacin has a low proarrhythmic potential. However, the hERG IC 50 and the ETPC unbound values are in the same concentration range. This would suggest a strong association with QT prolongation and TdP, as antiarrhythmic drugs prolonging repolarization. The hESC-CM model as used here would have accurately predicted the risk by showing drug-induced QT prolongation but only at concentrations higher than the ETPC unbound. The data for both verapamil and sparfloxacin underscore the necessity of a human model system that displays the full complexity of the human cardiomyocyte.
In conclusion, our results indicate that electrophysiological properties and drug responses of hESC-CM match clinical observations on QT prolongation/shortening and arrhythmia at similar concentrations. We showed here that by using FPD prolongation as a readout hESC-CM flags adverse drug effects with greater confidence than standard hERG in vitro assays. Screening a wider variety of drugs under defined conditions would further validate and identify the strengths and weaknesses of the system. Ultimately this should lead to the definition of a safety margin which can be instrumental for improving preclinical decision making and reducing drug development costs.
Materials and methods
Cell culture and differentiation HES3 cells (Costa et al., 2005) were routinely cultured on 129SV mouse embryonic fibroblast (MEFs) to maintain pluripotency and induced to differentiate to cardiomyocytes as described previously (Mummery et al., 2003; . Large numbers of contracting areas are obtained within 12 days that routinely consist of 20-25% cardiomyocytes and 75-80% endodermal cells and other mesodermal derivatives but no neural cells.
Patch clamp electrophysiology
Patch clamp electrophysiology was essentially done as described previously Moore et al., 2005) . Briefly, beating clumps of cardiomyocytes were dissociated using a collagenase-based method. Cardiomyocytes were plated on gelatin-coated glass and measured between 7 and 14 days after plating. Microelectrodes with a resistance between 1 and 3 MΩ were made from borosilicate glass (Clark Electrical Instruments, GC-150 T) with a Flaming/ Brown Micropipette Puller Model 80 (Sutter Instruments, CA). During electrophysiological measurements they were kept in a DMEM/F12-based medium without serum or phenol red. The pipette contained buffer consisting of 145 mM KCl, 5 mM NaCl, 2 mM CaCl 2 , 4 mM EGTA, 2 mM MgCl 2 , and 10 mM HEPES, adjusted to pH 7.30 with KOH.
MEA electrophysiology
MEA chips were plasma-cleaned and coated with fibronectin for 1 h at 37°C. Clumps of beating hESC-CM clusters were microdissected and replated on standard 60 electrode MEAs or alternatively 6-well MEAs. Extracellular recording was performed using a MEA1060INV MEA amplifier (Multi Channel Systems, Reutlingen, Germany). Output signals were digitized at 10 kHz by use of a PC equipped with a MC-card data acquisition board (Multi Channel Systems). Standard measurements were performed in DMEM supplemented with 5% FCS. During recordings, temperature was kept at 37°C. Data were recorded using QT-screen (Multi Channel Systems,) and analyzed off-line with QT-analyzer (Multi Channel Systems).
Data processing
Field potential duration or sodium amplitude data from at least three independent beating areas were averaged using GraphPad Prism software. Datapoints are displayed as mean ± SEM. Curves were fitted using the one phase decay algorithm; 95% confidence intervals are plotted as dashed lines.
Compounds
Lidocaine, nifedipine, E-4031, cisapride monohydrate, quinidine and verapamil hydrochloride, D,L-sotalol, sparfloxacin, sertindole, terfenadine, domperidone, and ketoconazole were obtained from Sigma-Aldrich. The substances were dissolved DMSO at 10 mM and serial dilutions were made in medium. The highest concentration of DMSO is reached at 30 μM drug which represents 0.3% DMSO. Measurements were started after a wash-in time of 2 min. supported by the Bsik Dutch Platform for Tissue Engineering, Bsik Stem Cells in Development and Disease, European Community's Sixth Framework Programme contract ("Heart-Repair") LSHM-CT-2005-018630 NWO Grant 114000101.
